Oxford Biomedica PLC 2023 AR2
The report highlights Oxford Biomedica's strategic transformation in 2023 into a global pure-play cell and gene therapy CDMO under the new 'One OXB' strategy. Key achievements include a 50% increase in the contracted value of client orders to £131 million (excluding COVID-19 vaccine manufacturing) and the expansion of its global site network, including the post-period acquisition of ABL Europe in France. Financially, total revenues decreased by 36% to £89.5 million due to the non-recurrence of vaccine manufacturing, resulting in an operating loss of £184.2 million, which was also impacted by a £99.3 million impairment of the US business. The company also committed to the Science Based Targets initiative (SBTi) and completed its Scope 3 emissions baseline.
Company: Oxford Biomedica PLC
Sector: Health Care
Country: United Kingdom
Year: 2023
Type: AR2
Pages: 181
Oxford Biomedica PLC
Annual Report And Accounts
The report highlights Oxford Biomedica's strategic transformation in 2023 into a global pure-play cell and gene therapy CDMO under the new 'One OXB' strategy. Key achievements include a 50% increase in the contracted value of client orders to £131 million (excluding COVID-19 vaccine manufacturing) and the expansion of its global site network, including the post-period acquisition of ABL Europe in France. Financially, total revenues decreased by 36% to £89.5 million due to the non-recurrence of vaccine manufacturing, resulting in an operating loss of £184.2 million, which was also impacted by a £99.3 million impairment of the US business. The company also committed to the Science Based Targets initiative (SBTi) and completed its Scope 3 emissions baseline.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Women on Board
Women in Management
Net Zero Target
Employees